Spyre Therapeutics
SYRE· Manufacturing· Fiscal year ends in December
Cameron Turtle is the CEO of Spyre Therapeutics and was paid $6.7M in FY2025 (Dec), down 4%.
Executives4
See all- 1Cameron TurtleChief Executive OfficerFY2025
- 2Sheldon SloanChief Medical OfficerFY2025
- 3Heidy King-JonesChief Legal Officer and Corporate SecretaryFY2025
- 4Scott BurrowsChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allSpyre Therapeutics paid its 4 named executives $13.3M in total in FY2025 (Dec). CEO Cameron Turtle was paid $6.7M of that.
| Name | |||
|---|---|---|---|
| Cameron TurtleChief Executive Officer | |||
| Sheldon SloanChief Medical Officer | Not disclosed | ||
| Heidy King-JonesChief Legal Officer and Corporate Secretary | |||
| Scott BurrowsChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Spyre Therapeutics names 18 peer companies for pay. Among Spyre Therapeutics and these peers, CEO pay was 5th highest of 7 and total shareholder return was the lowest of 7.
5th highest of 7in Spyre Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
7th highest of 7in Spyre Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 10, 2026 | FY2025 |
| Annual report | 10-K | Feb 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 14, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 1, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
